Leerink Partnrs Analysts Lower Earnings Estimates for Abivax

Key Points

• Leerink Partners has significantly lowered its FY2025 earnings forecast for Abivax, expecting earnings per share to be ($3.65), down from a previous estimate of ($3.36).
• Despite the negative earnings forecast, multiple analysts, including Guggenheim and Lifesci Capital, have raised their price targets for Abivax, indicating a consensus buy rating.
• Hedge funds have shown increasing interest in Abivax, with substantial increases in holdings from firms like Woodline Partners and Millennium Management, reflecting a growing confidence in the company's stock.

Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report) - Leerink Partnrs reduced their FY2025 earnings per share (EPS) estimates for shares of Abivax in a research note issued on Wednesday, July 23rd. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($3.65) per share for the year, down from their prior estimate of ($3.36). The consensus estimate for Abivax's current full-year earnings is ($2.83) per share. Leerink Partnrs also issued estimates for Abivax's Q4 2025 earnings at ($1.75) EPS, FY2026 earnings at ($3.54) EPS, FY2027 earnings at ($3.00) EPS, FY2028 earnings at ($1.89) EPS and FY2029 earnings at $1.16 EPS.

A number of other analysts also recently commented on ABVX. Piper Sandler increased their price target on Abivax from $70.00 to $112.00 and gave the company an "overweight" rating in a research report on Tuesday. Leerink Partners set a $74.00 target price on Abivax and gave the stock an "outperform" rating in a research report on Wednesday, July 23rd. Citigroup reaffirmed a "market outperform" rating on shares of Abivax in a report on Friday, July 18th. JMP Securities raised their price target on Abivax from $33.00 to $95.00 and gave the stock a "market outperform" rating in a report on Wednesday, July 23rd. Finally, Guggenheim lifted their price objective on Abivax from $50.00 to $101.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $86.00.

Abivax Price Performance

NASDAQ ABVX traded up $3.51 on Friday, reaching $70.08. The company had a trading volume of 1,339,455 shares, compared to its average volume of 587,234. The company's fifty day moving average is $12.24 and its 200 day moving average is $8.55. Abivax has a 52-week low of $4.77 and a 52-week high of $72.90. The company has a current ratio of 1.25, a quick ratio of 1.25 and a debt-to-equity ratio of 1.29.

Institutional Investors Weigh In On Abivax

Several institutional investors have recently added to or reduced their stakes in the company. Woodline Partners LP increased its holdings in Abivax by 319.5% during the 1st quarter. Woodline Partners LP now owns 201,924 shares of the company's stock valued at $1,262,000 after purchasing an additional 153,788 shares during the period. Octagon Capital Advisors LP purchased a new position in Abivax during the 1st quarter valued at about $7,688,000. Millennium Management LLC increased its holdings in Abivax by 6.0% during the 1st quarter. Millennium Management LLC now owns 987,414 shares of the company's stock valued at $6,171,000 after purchasing an additional 56,235 shares during the period. Allostery Investments LP increased its holdings in Abivax by 86.0% during the 1st quarter. Allostery Investments LP now owns 1,099,654 shares of the company's stock valued at $6,873,000 after purchasing an additional 508,401 shares during the period. Finally, ADAR1 Capital Management LLC increased its holdings in Abivax by 46.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 2,210,019 shares of the company's stock valued at $13,813,000 after purchasing an additional 696,626 shares during the period. Hedge funds and other institutional investors own 47.91% of the company's stock.

About Abivax

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.